Cargando…

TRIB2 contributes to cisplatin resistance in small cell lung cancer

Small cell lung cancer (SCLC) is the most aggressive lung-cancer subtype and so far, no favorable therapeutic strategy has been established for chemo-resistant SCLC. Cisplatin is one of the most important components among all standard poly-chemotherapeutic regimens for SCLC; therefore, this study fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Yuanxin, Yu, Dong, Perez-Soler, Roman, Klostergaard, Jim, Zou, Yiyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752545/ https://www.ncbi.nlm.nih.gov/pubmed/29312632 http://dx.doi.org/10.18632/oncotarget.22741

Ejemplares similares

Aerosol Azacytidine Inhibits Orthotopic Lung Cancers in Mice through Its DNA Demethylation and Gene Reactivation Effects
por: Qiu, Xuan, et al.
Publicado: (2014)

Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity
por: Wang, Lihui, et al.
Publicado: (2017)

High glucose contributes to the proliferation and migration of non-small-cell lung cancer cells via GAS5-TRIB3 axis
por: Ding, Cheng-Zhi, et al.
Publicado: (2018)

The Critical Role of TRIB2 in Cancer and Therapy Resistance
por: Mayoral-Varo, Victor, et al.
Publicado: (2021)

Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis
por: Shahrouzi, Parastoo, et al.
Publicado: (2020)

EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis
por: Fan, Chi-Chen, et al.
Publicado: (2020)

TRIB3 facilitates glioblastoma progression via restraining autophagy
por: Tang, Zhanbin, et al.
Publicado: (2020)

Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance
por: Machado, Susana, et al.
Publicado: (2020)

Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer
por: Cui, Yong, et al.
Publicado: (2018)

LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma
por: Wang, Junbin, et al.
Publicado: (2020)

Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer
por: Ma, Ying, et al.
Publicado: (2023)

Oncogenic TRIB2 interacts with and regulates PKM2 to promote aerobic glycolysis and lung cancer cell procession
por: Liu, Yuan-Rong, et al.
Publicado: (2022)

Capsaicin-induced TRIB3 upregulation promotes apoptosis in cancer cells
por: Lin, Rong-Jaan, et al.
Publicado: (2018)

TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
por: Yu, Jiao-jiao, et al.
Publicado: (2020)

TRIB3 Promotes Lung Adenocarcinoma Progression via an Enhanced Warburg Effect
por: Xing, Yutong, et al.
Publicado: (2020)

IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and dna repair associated molecules
por: Duan, Shanzhou, et al.
Publicado: (2015)

A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer
por: Yang, Li, et al.
Publicado: (2016)

RFWD2 Knockdown as a Blocker to Reverse the Oncogenic Role of TRIB2 in Lung Adenocarcinoma
por: Hao, Ruimin, et al.
Publicado: (2021)

WP1130 attenuates cisplatin resistance by decreasing P53 expression in non–small cell lung carcinomas
por: Wang, Xiang, et al.
Publicado: (2017)

Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance
por: Su, Yinjie, et al.
Publicado: (2019)

TRIB2 regulates normal and stress-induced thymocyte proliferation
por: Liang, Kai Ling, et al.
Publicado: (2016)

Regulation of TRIB3 mRNA and Protein in Breast Cancer
por: Wennemers, Marloes, et al.
Publicado: (2012)

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis
por: Xu, Jie, et al.
Publicado: (2014)

TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways
por: Singh, Karnika, et al.
Publicado: (2023)

Role of TRIB3 in Diabetic and Overnutrition-Induced Atherosclerosis
por: Sowers, James R.
Publicado: (2012)

TRIB3-P62 interaction, diabetes and autophagy
por: Hua, Fang, et al.
Publicado: (2015)

Evidence for a role of TRIB3 in the regulation of megakaryocytopoiesis
por: Butcher, Lee, et al.
Publicado: (2017)

The Pseudokinase TRIB1 in Immune Cells and Associated Disorders
por: Danger, Richard, et al.
Publicado: (2022)

UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance
por: Jin, Chengmeng, et al.
Publicado: (2013)

Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5)
por: Wei, Dong, et al.
Publicado: (2022)

Tribbles pseudokinase 3 (TRIB3) contributes to the progression of hepatocellular carcinoma by activating the mitogen-activated protein kinase pathway
por: Wang, Rui-Qi, et al.
Publicado: (2021)

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells
por: Höhn, Annika, et al.
Publicado: (2016)

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells
por: Guo, Jiwei, et al.
Publicado: (2018)

Bioenergetics of acquired cisplatin resistant H1299 non-small cell lung cancer and P31 mesothelioma cells
por: Geoghegan, Fintan, et al.
Publicado: (2017)

Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798
por: Yang, Xuemei, et al.
Publicado: (2017)

TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
por: Hill, Richard, et al.
Publicado: (2017)

Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2
por: O’Connor, Caitriona, et al.
Publicado: (2018)

Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival
por: Dai, Chun-Hua, et al.
Publicado: (2016)

EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
por: Gao, Jing, et al.
Publicado: (2016)

Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer
por: Wangpaichitr, Medhi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lcfqso0jl2gun03d7jd2og3ts0